Find a Doctor

Rachel Tangen, PhD

Rachel Tangen, PhD

Ratings

(0)

0 Ratings 0 Reviews

Specialty

Pediatric Neuropsychology

Accepting New Patients

Schedule an Appointment

(216)844-3230

Request a Call Back

Biography

Rachel Tangen, PhD, is a pediatric neuropsychologist in the Division of Developmental and Behavioral Pediatrics and Psychology at University Hospitals Rainbow Babies & Children's Hospital. She is Assistant Professor, Pediatrics, Case Western Reserve University School of Medicine.

Dr. Tangen is board certified in clinical neuropsychology through the American Board of Professional Psychology. Her special interests include neuropsychological assessment of the cognitive and behavioral outcomes of pediatric brain Injury, cochlear implantation in children, genetic disorders, fetal alcohol spectrum disorders, epilepsy, attention deficit hyperactivity disorder (ADHD) and spina bifida. She was named to the medical staff of UH Rainbow Babies & Children's Hospital in 2006.

Dr. Tangen is a cum laude graduate of the University of Minnesota-Twin Cities with a degree in psychology and physiology. She earned a master’s degree and a doctorate in clinical psychology, specializing in clinical neuropsychology, from the University of Houston, Houston, Texas. Before beginning her doctorate program, she served an internship in neuropsychology at the University of Florida Health Science Center, Gainesville, Fla. After completing the program, she served a postdoctoral fellowship in neuropsychology at Children’s Hospital, New Orleans, La.

Her research interests include hearing impairment in children and its effects on cognitive development, cognitive effects of genetic disorders, cognitive and behavioral effects of fetal alcohol spectrum disorders, cognitive and behavioral outcomes in children with epilepsy, cognitive effects of spina bifida, and cognitive and behavioral effects of pediatric head trauma.

Dr. Tangen currently is a co-investigator on a nationally funded study on urea cycle disorders in children. She also is a co-investigator on several studies of new drugs used to treat urea cycle disorders and phenylketonuria (PKU). She is also a principal investigator for a study of developmental delays in children with hearing loss who are candidates for a cochlear implant and on a study examining the cognitive and behavioral effects of fetal alcohol spectrum disorders.

She has presented abstracts about her research at national medical meetings and speaks frequently at local seminars and courses on fetal alcohol spectrum disorder, epilepsy and other neuropsychological disorders.

Dr. Tangen is a member of the International Neuropsychological Society, National Academy of Neuropsychology, Ohio Psychological Association and the American Academy of Clinical Neuropsychology.

Research Interests

Hearing impairment in children and its effects on cognitive development
Fetal alcohol spectrum disorder
Pediatric epilepsy
Cognitive effects of genetic disorders
Spina bifida
Pediatric head trauma

Expertise

  • Cognitive Effects of Cochlear Implantation
  • Cognitive Effects of Congenital Hydrocephalus
  • Cognitive Effects of Congenital Spina Bifida
  • Cognitive Effects of Metabolic Disorders
  • Fetal Alcohol Spectrum Disorder
  • Neuropsychological Assessment
  • Pediatric Epilepsy

Office Locations

10524 Euclid Ave
Cleveland OH, 44106

Get Directions

Patient Satisfaction Reviews

0 out of 5

0 Ratings

Education

Post Doctorate Training | Neuropsychology
Neuropsychology - Children's Hospital New Orleans (2004 - 2006)

Internship | Psychology
Psychology - Shands At The University Of Florida (2003 - 2004)

Professional Education
University Of Houston (2004)

Other Education
University Of Houston (2002)

Undergraduate
University Of Minnesota, Twin Cities (1997)

Industry Relationships

University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.

UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.

View UH’s policy (PDF) on practitioner-industry relationships.

As of December 31, 2016, Rachel Tangen did not disclose any Outside Relationships with Industry.